Amgen to discontinue discounts on anemia drug: report (Reuters)
Reuters - Amgen Inc is halting some pricing practices that critics say were contributing to overuse of its flagship anemia drug Aranesp at a time of mounting concerns about the product’s safety, the New York Times said.
More: continued here
Recent Entries
- Senate passes $149 billion for jobless aid (Reuters)
- Watchdog: GMAC bailout could cost taxpayers $6.3B (AP)
- Japan to oppose global trade ban on Atlantic bluefin tuna (AFP)
- China inflation accelerates in February (AP)
- Foreclosure rates up by smallest amount in 4 years (AP)
- Credit card users: Not so responsible after all? (AP)
- 2-second video causes headache for ABC News (AP)
- Home loan demand nudges higher in latest week (Reuters)
- Colorado unemployment rate edges up to 7.4 percent (AP)
- Budget deficit sets record in February (AP)
